EGFR and breast carcinoma: Following treatment with trastuzumab or a dual epidermal growth factor receptor (EGFR)/ErbB2 tyrosine kinase inhibitor (TKI; i.e., lapatanib), in a range of HER2 positive breast cancer cell lines, HER2 was downregulated, while the Notch activity was upregulated.